- Home
- EDSA vs SNTI Comparison
EDSA vs SNTI Comparison
Compare EDSA & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- SNTI
- Stock Information
- Founded
- EDSA 2015
- SNTI 2016
- Country
- EDSA Canada
- SNTI United States
- Employees
- EDSA N/A
- SNTI N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- SNTI Health Care
- Exchange
- EDSA Nasdaq
- SNTI Nasdaq
- Market Cap
- EDSA 17.2M
- SNTI 39.6M
- IPO Year
- EDSA N/A
- SNTI N/A
- Fundamental
- Price
- EDSA $2.39
- SNTI $1.40
- Analyst Decision
- EDSA Strong Buy
- SNTI Strong Buy
- Analyst Count
- EDSA 2
- SNTI 2
- Target Price
- EDSA $13.00
- SNTI $8.50
- AVG Volume (30 Days)
- EDSA 16.6K
- SNTI 126.3K
- Earning Date
- EDSA 08-08-2025
- SNTI 11-13-2025
- Dividend Yield
- EDSA N/A
- SNTI N/A
- EPS Growth
- EDSA N/A
- SNTI N/A
- EPS
- EDSA N/A
- SNTI N/A
- Revenue
- EDSA N/A
- SNTI N/A
- Revenue This Year
- EDSA N/A
- SNTI N/A
- Revenue Next Year
- EDSA N/A
- SNTI $150.00
- P/E Ratio
- EDSA N/A
- SNTI N/A
- Revenue Growth
- EDSA N/A
- SNTI N/A
- 52 Week Low
- EDSA $1.55
- SNTI $1.26
- 52 Week High
- EDSA $5.00
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- EDSA 51.55
- SNTI 39.08
- Support Level
- EDSA $2.41
- SNTI $1.33
- Resistance Level
- EDSA $2.47
- SNTI $1.39
- Average True Range (ATR)
- EDSA 0.09
- SNTI 0.08
- MACD
- EDSA -0.01
- SNTI 0.02
- Stochastic Oscillator
- EDSA 48.15
- SNTI 38.57
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.